Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
Inflamm Bowel Dis. 2013 Mar;19(3):669-71. doi: 10.1097/MIB.0b013e31827e7a0f.
Venous thromboembolism is a relatively common and potentially serious complication in inpatients with inflammatory bowel disease (IBD). There are a number of pathophysiologic mechanisms for venous thromboembolism that are specific to patients with IBD that may be active. The use of anticoagulants for prophylaxis against venous thromboembolism in hospitalized patients with IBD needs to be balanced against the potential for worsening of rectal bleeding. Evidence from randomized trials suggests that heparin and low-molecular weight heparin are generally safe to use in patients with active IBD, and a number of guidelines support their use for thromboprophylaxis in this patient population.
静脉血栓栓塞症是炎症性肠病（IBD）住院患者中相对常见且潜在严重的并发症。有许多与 IBD 患者相关的特定于静脉血栓栓塞症的病理生理机制可能处于活跃状态。对于 IBD 住院患者，预防静脉血栓栓塞症使用抗凝剂需要与潜在的直肠出血恶化相平衡。随机试验的证据表明，肝素和低分子量肝素在活动性 IBD 患者中通常安全使用，许多指南支持在该患者人群中使用它们进行血栓预防。
